Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gamulescu MA et al. – GLD did not change significantly. Patients with exudative AMD of all subtypes benefit from intravitreal anti–VEGF injections. No significant difference between bevacizumab and ranibizumab is seen in the short–term follow–up.

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address